SAJE Pharma
SAJE Pharma is an emerging biopharmaceutical company focused on developing new therapeutic agents for unmet medical needs that provide significant benefits over currently available therapies.
SAJE Pharma has license to innovative compounds that target the nitric oxide signaling system and its modulation of vascular and pulmonary function. The current research efforts of the company are targeted towards respiratory diseases such as asthma and COPD, cardiovascular disease such as hypertension, and inflammation.
With management and advisors on the cutting edge of nitric oxide research, SAJE Pharma is positioned to be the leader in the development of new therapies for vascular and pulmonary diseases. The management team has in depth drug development expertise, including global pharmaceutical development, preclinical development, regulatory affairs, clinical development, drug manufacturing and commercialization.
This broad range of expertise enables SAJE Pharma to move development projects forward that provide the greatest potential for clinical benefit and success. It is the goal of SAJE Pharma to manage our programs through to the early phases of clinical development via innovative approaches and strategies. The progression of our programs in the most time and cost efficient manner will rapidly build company value and will expedite the availability of these novel therapies to patients.
